Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.66 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.66 |
| ▸ | PI4KA | P42356 | 2/20 | 0.52 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.52 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.52 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | DRD3 | P35462 | 1/20 | 0.52 |
| ▸ | XDH | P47989 | 1/20 | 0.52 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.52 |
| ▸ | CDK2 | P24941 | 3/20 | 0.47 |
| ▸ | DPP4 | P27487 | 1/20 | 0.47 |
| ▸ | PNP | P00491 | 1/20 | 0.46 |
| ▸ | POLA1 | P09884 | 2/20 | 0.43 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.43 |
| ▸ | CDK1 | P06493 | 2/20 | 0.41 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.41 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.41 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.41 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8851 | 1.00 | PDPK1 (0.66) | PDPK1GDAPI4KAPI4K2BPI4K2A | |
| SCHEMBL3328527 | 0.90 | PDPK1 (0.54) | PDPK1GDAPI4KAPI4K2BPI4K2A | |
| Isoguanine SCHEMBL29569323 | 0.80 | PDPK1 (0.66) | PDPK1GDAPI4KAPI4K2BPI4K2A | |
| Isoguanine SCHEMBL887741 | 0.80 | PDPK1 (0.66) | PDPK1GDAPI4KAPI4K2BPI4K2A | |
| 2,6-Diaminopurine SCHEMBL24053 | 0.79 | PDPK1 (1.00) | PDPK1GDAPI4KAPI4K2BPI4K2A | |
| SCHEMBL2526552 | 0.79 | PDPK1 (0.44) | PDPK1GDAPI4KAPI4K2BPI4K2A | |
| Ribose (Furanose) SCHEMBL4284369 | 0.79 | HIF1A (0.46) | PDPK1GDAPI4KAPI4K2BPI4K2A | |
| SCHEMBL29993917 | 0.78 | PDPK1 (0.63) | PDPK1GDAPI4KAPI4K2BPI4K2A | |
| 2,6-Diaminopurine SCHEMBL8757979 | 0.78 | PDPK1 (0.96) | PDPK1GDAPI4KAPI4K2BPI4K2A | |
| 2,6-Diaminopurine SCHEMBL27891733 | 0.78 | PDPK1 (0.96) | PDPK1GDAPI4KAPI4K2BPI4K2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4680228-A2 | OPHTHALMIC CREAM FORMULATIONS AND THEIR USES | Glaukos Corporation (US) | 2026-01-21 | — | — | EP | claimed |
| WO-2025199647-A1 | C4'-MODIFIED NUCLEOSIDE ANALOGUES AND SYNTHETIC METHODS | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2025-10-02 | — | — | WO | claimed |
| EP-3980554-B1 | HYBRIDIZING ALL-LNA OLIGONUCLEOTIDES | HOFFMANN LA ROCHE (CH) | 2025-03-26 | — | — | EP | claimed |
| WO-2024192323-A2 | OPHTHALMIC CREAM FORMULATIONS AND THEIR USES | GLAUKOS CORPORATION (US) | 2024-09-19 | — | — | WO | claimed |
| WO-2024124190-A1 | ENGINEERED MICROORGANISMS FOR DELIVERY OF THERAPEUTIC AGENTS | MICROBIAL MACHINES, INC. (US) | 2024-06-13 | — | — | WO | claimed |
| EP-3980554-A1 | HYBRIDIZING ALL-LNA OLIGONUCLEOTIDES | F. Hoffmann-La Roche AG (CH) | 2022-04-13 | — | — | EP | claimed |
| EP-4735459-A1 | METHODS AND INTERMEDIATES FOR PREPARING ANTIVIRAL PRODRUGS | GILEAD SCIENCES, INC. (US) | 2026-05-06 | — | — | EP | disclosed |
| US-20260035675-A1 | ENGINEERED SUCROSE PHOSPHORYLASE VARIANT ENZYMES | CODEXIS, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| US-20260009012-A1 | ENGINEERED PHOSPHOPENTOMUTASE VARIANT ENZYMES | CODEXIS, INC. (US) | 2026-01-08 | — | — | US | disclosed |
| US-12480104-B2 | Engineered sucrose phosphorylase variant enzymes | CODEXIS, INC. (US) | 2025-11-25 | — | — | US | disclosed |
| US-12453760-B2 | Enhanced therapeutic usage of a purine nucleoside phosphorylase or nuceloside hydrolase prodrug | THE UAB RESEARCH FOUNDATION (US) | 2025-10-28 | — | — | US | disclosed |
| WO-2025199647-A1 | C4'-MODIFIED NUCLEOSIDE ANALOGUES AND SYNTHETIC METHODS | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2025-10-02 | — | — | WO | disclosed |
| US-12421509-B2 | Engineered phosphopentomutase variant enzymes | CODEXIS, INC. (US) | 2025-09-23 | — | — | US | disclosed |
| US-11337991-B2 | Methods for the treatment and prophylaxis of HIV and AIDS | MERCK SHARP & DOHME CORP. (US) | 2022-05-24 | — | — | US | disclosed |
| EP-3993824-A1 | ENGINEERED SUCROSE PHOSPHORYLASE VARIANT ENZYMES | Codexis, Inc. (US) | 2022-05-11 | — | — | EP | disclosed |
| WO-2022081541-A1 | COMPOSITIONS AND METHODS INVOLVING ANTIBODY CONSTRUCTS | CHAN ZUCKERBERG BIOHUB, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| WO-2022076454-A1 | ENGINEERED PHOSPHOPENTOMUTASE VARIANT ENZYMES | CODEXIS, INC. (US) | 2022-04-14 | — | — | WO | disclosed |
| EP-3980554-A1 | HYBRIDIZING ALL-LNA OLIGONUCLEOTIDES | F. Hoffmann-La Roche AG (CH) | 2022-04-13 | — | — | EP | disclosed |
| CN-114072165-A | Engineered sucrose phosphorylase variant enzymes | 科德克希思公司 | 2022-02-18 | — | — | CN | disclosed |
| US-20220031817-A1 | ENHANCED THERAPEUTIC USAGE OF A PURINE NUCLEOSIDE PHOSPHORYLASE OR NUCELOSIDE HYDROLASE PRODRUG | THE UAB RESEARCH FOUNDATION (US) | 2022-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260035675-A1 | ENGINEERED SUCROSE PHOSPHORYLASE VARIANT ENZYMES | RNGTT, PNP, GYS1 | PDPK1 986/4885GDA 125/4885PI4KA 761/4885 |
| US-20260009012-A1 | ENGINEERED PHOSPHOPENTOMUTASE VARIANT ENZYMES | PPME1, PPA1, ITPA | PDPK1 2134/4885GDA 173/4885PI4KA 409/4885 |
| US-11337991-B2 | Methods for the treatment and prophylaxis of HIV and AIDS | XDH, RTF1, HPRT1 | PDPK1 4521/4885GDA 909/4885PI4KA 4709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.